Edition:
United States

SciGen Ltd (SIE.AX)

SIE.AX on Australia Stock Exchange

0.06AUD
--
Change (% chg)

-- (--)
Prev Close
$0.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
24,612
52-wk High
$0.07
52-wk Low
$0.01

Summary

Name Age Since Current Position

Marek Dziki

2016 Chairman of the Board

Ashley Morris

2017 Chief Executive Officer, Executive Director

Adam Polonek

38 2017 Chief Financial Officer, Executive Director, Company Secretary

Yvonne Lim

2010 Group Financial Controller

Jean-Claude Balducci

Country Manager, Australia and New Zealand

Liza Domingo

Country Manager, Philippines

Li Minyi

2011 Accounts Executive

Hedy Ong

2011 Finance and Logistics Manager

Marcus Poh

Regional Marketing Manager

Chander Sharma

Business Development Executive

Edward Thomas

2011 Business Development Executive

Sharon Walters

Business Development Executive

Leng Wong Lai

2002 Company Secretary

Marcin Dukaczewski

38 2008 Non-Executive Director

Mateusz Kosecki

40 2009 Non-Executive Director

Jubo Liu

2017 Non-Executive Director

Vaidyanathan Viswanath

2017 Non-Executive Director

Kenneth Gross

85 Independent Non-Executive Director

Biographies

Name Description

Marek Dziki

Dr. Marek Dziki is the Chairman of the Board of the Board of the Company. Dr. Marek Dziki, is a medical doctor with a PhD from the University in Lublin, Poland. In 1998 he completed his MBA at the International Business School in Warsaw and in 2005 completed another MBA from Merck University (Kellog Business School, Chicago, Hong Kong University of Science and Technology and Business School in Fountaineblue.

Ashley Morris

Mr. Ashley Ivor Simon Morris is Chief Executive Officer, Executive Director of the Company. Mr. Morris has over 30 years’ experience within the pharmaceutical industry in the Asia Pacific. He is ideally suited to lead SciGen’s growth initiatives and drive the transformation process. Morris has a B.A. Hons. in Politics & Economics from Nottingham University. From 2010 to 2013, Mr. Morris was the Managing Director of Bausch & Lomb covering Asean countries. From 2004 to 2009 he was with Schering-Plough starting as Area Director for South Asia and progressed to General Manager for Malaysia and Singapore. From 2001 to 2003, he was the Vice President for South Asia in Pharmacia. From 1978 to 2001, he held several positions in other Pharmaceutical companies such as Beecham, Farmitalia Carlo Erba, Pharmacia Asia and Pharmacia Philippines.

Adam Polonek

Mr. Adam Tomasz Polonek served as Chief Financial Officer, Executive Director, Company Secretary of SciGen Ltd. He is a graduate of the Economic Faculty at Academy of Economics in Poland. Mr. Polonek joined Bioton S.A. in 2006 as Deputy Finance Director and since April 2009 as the Finance Director. He was appointed to the position of Chief Financial Officer of SciGen Ltd in January 2013 and holds finance-related positions in other subsidiaries of SciGen and the Bioton Group. Mr. Polonek’s professional experience includes successful career in one of the leading investment bank in CEE Europe, CAIB Financial Advisers, which is part of the leading banking Group Unicredit in Europe. During Mr. Polonek’s career, he was involved in several Corporate Finance transactions and he has vast experience in stock exchange markets.

Yvonne Lim

Jean-Claude Balducci

Liza Domingo

Li Minyi

Hedy Ong

Marcus Poh

Chander Sharma

Edward Thomas

Sharon Walters

Leng Wong Lai

Marcin Dukaczewski

Mr. Marcin Dukaczewski serves as Non-Executive Director of SciGen Ltd since December 26, 2008. Mr. Marcin Dukaczewski was trained in International Political and Economical Relations at the Warsaw University (Uniwersytet Warszawski). Mr. Dukaczewski holds the position of Vice President of the Management Board of Prokom Investments – a Polish private-equity fund being the strategic investor in Bioton S.A. He is also a member of the Supervisory Board of public listed companies listed on the Warsaw Stock Exchange: Bioton (biotechnology), Petrolinvest (oil & gas exploration) and Polnord (real estate development). Mr. Dukaczewski is also a member of the Supervisory Board of Biolek (veterinary products), Silurian (shale gas exploration) and a member of the Board of Directors of Biolek, Inc in Canada.

Mateusz Kosecki

Mr. Mateusz Patryk Kosecki serves as Non-Executive Director of SciGen Ltd since December 1, 2009. Mr. Mateusz Kosecki is a graduate of the Executive MBA Program of European University, Montreux, Switzerland. He is the Foreign Markets Director of Bioton S.A. and is responsible for the operations of the company on overseas market. He is also the Vice President of Biolek Sp z.o.o., a member of Bioton Group. Mr. Kosecki has experience in international business. From 1995 to 1996 he worked as the Marketing Manager in Lenex Company in Sofia, Bulgaria. From 1997 to 2001 he was Head of Foreign Corporate Governance and Operations of Ciech S.A. He has been connected with pharmaceutical industry for 10 years. From 2002 to 2006, as the Country Manager for Russia of the Polish pharmaceutical company Ciech Polfa, and from 2006 to 2009 as Regional Director for Eastern Europe in Bioton S.A.

Jubo Liu

Dr. Ju Bo Liu is the Non-Executive Director of the Company. He is President of the Managing Board of Bioton SA. Dr. Liu is the founder and has served as the CEO of Cogenes Biotechnology Incorporation (focused on In vitro diagnosis R&D, manufacturing and marketing) since August 2011 and Is the founder and CEO of NovoTek Pharmaceuticals Limited (Hong Kong) and Beijing NovoTek Medicinal Technology Development Co. Ltd (Beijing) (international platform to globalise healthcare products both from within and outside of China) since August 2009. From April 2008 to July 2009 he was the China Chief Representative of Immtech Pharmaceuticals Inc. (US New York) (establishing Chinese activity infrastructure and Investment plans). From November 2007 to April 2008, he acted as a Clinical Trial Liaison with US-based Pharmaceuticals Inc. (US New York) carrying out global clinical trial operations in China. From October 2006 to November 2007 he was a scientist at Boston Vertex Pharmaceuticals Inc. (formulation and drug delivery). From July of 2005 to January of 2007 he was as a cofounder and served as the Director of Business Development of JCS Biopolytech Incorporation (modified blopolymer R&D and marketing used for drug delivery and nanotechnology). From August 1997 to February 2001, he served as the Director of Marketing and Regulatory Affairs for Huayuanlong Medicinal Technology Development Co. Ltd. of Beijing, China. Dr. Liu obtained his Bachelor's Degree in Pharmacy from the Department of Pharmacy of the Pharmaceutical University of Shenyang and a Ph.D. from the Department of Pharmaceutical Sciences at the University of Toronto. Furthermore, Dr. Liu is an author or co-author of several publications regarding medical and biological Issues.

Vaidyanathan Viswanath

Mr. Vaidyanathan Viswanath is Non-Executive Director of the Company. He is a post-graduate In Pharmacology with over 30 years’ experience in sales, marketing, business development and strategic planning in the pharmaceutical Industry across Asia. His previous experience includes Serum Institute - India and Astra - India both in sales and marketing, 8 years with Pharmacia - India and China. Upon completion of the global acquisition of Pharmacia by Pfizer in April 2003, he assumed the position of Director Business Development & Strategic Planning for Capsugel (a division of Pfizer) based in Bangkok until 2011. Currently living in Beijing, Mr.Viswanath is an Independent Consultant for a number of pharmaceutical companies and in this role offers his expertise in the area of Strategic Marketing, Business Development, Marketing and Sales Effectiveness, Alliance Management, KOL & Advocacy development. With his deep understanding of the trends in the industry backed up by his strong networking capabilities, Mr. Viswanath envisions to act as a bridge for these companies to reach out to companies overseas and vice versa. Mr Viswanath serves on Novotek’s Advisory board since 2012.

Kenneth Gross

Mr. Kenneth Gross is Independent Non-Executive Director of SciGen Ltd. Mr. Kenneth Gross co-founded Goldmark Plastic Compounds in 1957. The Company has since become a distributor of plastic raw materials within the United States. In addition, Mr. Gross holds a number of directorships in various companies involved in chemical, metals, engineering resins and lubricating oils.